The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

sodium diiodomethanesulfonate     sodium diiodomethanesulfonate

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of diiodomethanesulfonic acid


Psychiatry related information on diiodomethanesulfonic acid


High impact information on diiodomethanesulfonic acid


Chemical compound and disease context of diiodomethanesulfonic acid

  • Because of the improved clinical benefits, it is anticipated that the PEG Intron plus ribavirin combination therapy will become the new standard of care for the treatment of chronic hepatitis C [13].
  • Twenty-two patients with non-Hodgkin's lymphoma (NHL) were treated with a combined regimen of interferon alfa-2b (Intron A; Schering-Plough) and chlorambucil to evaluate the response and efficacy in pre-treated or relapsed patients [14].
  • Three exogenous proteins, the LRR domain of internalin B, the T4 lysozyme, and the Intron 8 gene product of the of the HER2 tyrosine kinase receptor were derivatized with appropriate bifunctional cross-linkers and conjugated to the virus capsid [15].
  • We have tested the ability of interferon alfa-2b (Intron A; Schering-Plough) to prolong remissions induced by busulfan in patients with chronic granulocytic leukemia (CGL) [16].
  • Intron 9 contains the complete endogenous retrovirus HERV-K(C4) as a 6.4-kb insertion in 60% of human C4 genes [17].

Biological context of diiodomethanesulfonic acid


Anatomical context of diiodomethanesulfonic acid

  • Intron-containing pre-tRNAs from organisms as different as yeast, Nicotiana, Xenopus and man are efficiently spliced and processed in a HeLa cell extract [23].
  • Intron-containing expression cassettes were transfected into a human cell line, and RNA transcripts were analyzed for intron removal [24].
  • Intron 1 enhancer activity alone is therefore insufficient to account for the discrepancy between endogenous transcript levels and core muscle promoter activity in immature and mature skeletal muscle and points to the existence of additional enhancer elements in other regions of the DMD gene [25].
  • A larger transcript containing Intron II was present in both cancers and normal mucosa but was barely discernible in the gastric antrum [26].
  • Intron-less RNA injected into the nucleus of Xenopus oocytes accesses a regulated translation control pathway [27].

Associations of diiodomethanesulfonic acid with other chemical compounds

  • Structural aspects of the human C5 gene. Intron/exon organization, 5'-flanking region features, and characterization of two truncated cDNA clones [28].
  • The efficacy of Ampligen was compared with that of the interferon inducer poly(inosinic acid)-poly(cytidylic acid) [poly(IC)], alpha interferon 2b (INTRON A), and pegylated alpha interferon 2b (PEG-INTRON-alpha-2b) [29].
  • We now report that a combination of recombinant interferon alpha (Intron; Schering) and retinoic acid is synergistically cytostatic for HL-60 cells [30].
  • The regimen studied consisted of 5-fluorouracil, 750 mg/M2/day, by continuous intravenous infusion on Days 1-5, and interferon-alpha-2b (Intron A), 5 x 10(6)U/M2/day, subcutaneously on Days 1, 3, and 5, repeated every 21 days [31].
  • Response, assessed based on viral load and liver enzymes, was compared to that of 27 patients (group B) who received Intron A 3 million units 3 times weekly and daily Ribavirin (same dose) for 12 months (standard regimen) [32].

Gene context of diiodomethanesulfonic acid


Analytical, diagnostic and therapeutic context of diiodomethanesulfonic acid

  • Intron degradation and exon ligation only occur in double mutants with restored base pairing between the gamma and gamma' sites [38].
  • The Sunbelt Melanoma Trial examines the therapeutic value of completion dissection and benefits of Intron A [39].
  • Since interferon alfa-2b (Intron A) is useful as a single agent, it is important to determine if interferon can be combined with standard chemotherapy to improve both response and survival in patients with cancer [40].
  • BLAST search of the NCBI mouse EST database and RT-PCR analysis uncovered two differentially spliced transcripts, "mcal-A" and "mcal-B." The two transcripts are identical, except that mcal-B contains a longer 3' untranslated region due to retention of a short intron (I5) between exons five and six [41].
  • This multicenter study reports on 128 patients with hairy cell leukemia (HCL) who were treated subcutaneously with alfa-2b interferon (Intron A, Schering Corp, Kenilworth, NJ), three times a week at a dosage of 2 megaunits/m2 [42].


  1. Intron mobility in the T-even phages: high frequency inheritance of group I introns promoted by intron open reading frames. Quirk, S.M., Bell-Pedersen, D., Belfort, M. Cell (1989) [Pubmed]
  2. Intron 22 inversions and haemophilia. Collins, P.W., Jenkins, P.V., Goldman, E., Lee, C.A., Pasi, K.J. Lancet (1994) [Pubmed]
  3. Intron-size constraint as a mutational mechanism in Rothmund-Thomson syndrome. Wang, L.L., Worley, K., Gannavarapu, A., Chintagumpala, M.M., Levy, M.L., Plon, S.E. Am. J. Hum. Genet. (2002) [Pubmed]
  4. Intron insertion facilitates amplification of cloned virus cDNA in Escherichia coli while biological activity is reestablished after transcription in vivo. Johansen, I.E. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  5. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. Golomb, H.M., Jacobs, A., Fefer, A., Ozer, H., Thompson, J., Portlock, C., Ratain, M., Golde, D., Vardiman, J., Burke, J.S. J. Clin. Oncol. (1986) [Pubmed]
  6. Intron 2 (T/C) CYP46 Polymorphism Is Associated with Alzheimer's Disease in Chinese Patients. Li, Y., Chu, L.W., Chen, Y.Q., Cheung, B.M., Leung, R.Y., Yik, P.Y., Ng, K.M., Mak, W., Jin, D.Y., St George-Hyslop, P., Song, Y.Q. Dementia and geriatric cognitive disorders (2006) [Pubmed]
  7. Associations among Race/Ethnicity, ApoC-III Genotypes, and Lipids in HIV-1-Infected Individuals on Antiretroviral Therapy. Foulkes, A.S., Wohl, D.A., Frank, I., Puleo, E., Restine, S., Wolfe, M.L., Dube, M.P., Tebas, P., Reilly, M.P. PLoS Med. (2006) [Pubmed]
  8. The DExH box protein Suv3p is a component of a yeast mitochondrial 3'-to-5' exoribonuclease that suppresses group I intron toxicity. Margossian, S.P., Li, H., Zassenhaus, H.P., Butow, R.A. Cell (1996) [Pubmed]
  9. Splicing of Balbiani ring 1 gene pre-mRNA occurs simultaneously with transcription. Baurén, G., Wieslander, L. Cell (1994) [Pubmed]
  10. Intron within the large rRNA gene of N. crassa mitochondria: a long open reading frame and a consensus sequence possibly important in splicing. Burke, J.M., RajBhandary, U.L. Cell (1982) [Pubmed]
  11. Intron size and natural selection. Carvalho, A.B., Clark, A.G. Nature (1999) [Pubmed]
  12. Bimolecular exon ligation by the human spliceosome. Anderson, K., Moore, M.J. Science (1997) [Pubmed]
  13. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Wang, Y.S., Youngster, S., Grace, M., Bausch, J., Bordens, R., Wyss, D.F. Adv. Drug Deliv. Rev. (2002) [Pubmed]
  14. Interferon alfa-2b and chlorambucil in the treatment of non-Hodgkin's lymphoma. Chisesi, T., Capnist, G., Vespignani, M., Cetto, G. Investigational new drugs. (1987) [Pubmed]
  15. Chemical conjugation of heterologous proteins on the surface of Cowpea mosaic virus. Chatterji, A., Ochoa, W., Shamieh, L., Salakian, S.P., Wong, S.M., Clinton, G., Ghosh, P., Lin, T., Johnson, J.E. Bioconjug. Chem. (2004) [Pubmed]
  16. Interferon alfa-2b in the treatment of chronic granulocytic leukemia. Bergsagel, D.E., Haas, R.H., Messner, H.A. Investigational new drugs. (1987) [Pubmed]
  17. The endogenous retroviral insertion in the human complement C4 gene modulates the expression of homologous genes by antisense inhibition. Schneider, P.M., Witzel-Schlömp, K., Rittner, C., Zhang, L. Immunogenetics (2001) [Pubmed]
  18. Expression of the split gene cob in yeast: evidence for a precursor of a "maturase" protein translated from intron 4 and preceding exons. Weiss-Brummer, B., Rödel, G., Schweyen, R.J., Kaudewitz, F. Cell (1982) [Pubmed]
  19. Determination of left/right asymmetric expression of nodal by a left side-specific enhancer with sequence similarity to a lefty-2 enhancer. Adachi, H., Saijoh, Y., Mochida, K., Ohishi, S., Hashiguchi, H., Hirao, A., Hamada, H. Genes Dev. (1999) [Pubmed]
  20. Intron mobility in phage T4 occurs in the context of recombination-dependent DNA replication by way of multiple pathways. Mueller, J.E., Clyman, J., Huang, Y.J., Parker, M.M., Belfort, M. Genes Dev. (1996) [Pubmed]
  21. The Receptor for Branch-Site Docking within a Group II Intron Active Site. Hamill, S., Pyle, A.M. Mol. Cell (2006) [Pubmed]
  22. Intron phylogeny: a new hypothesis. Cavalier-Smith, T. Trends Genet. (1991) [Pubmed]
  23. Wheat germ splicing endonuclease is highly specific for plant pre-tRNAs. Stange, N., Gross, H.J., Beier, H. EMBO J. (1988) [Pubmed]
  24. Evaluating group I intron catalytic efficiency in mammalian cells. Long, M.B., Sullenger, B.A. Mol. Cell. Biol. (1999) [Pubmed]
  25. Identification of a transcriptional enhancer within muscle intron 1 of the human dystrophin gene. Klamut, H.J., Bosnoyan-Collins, L.O., Worton, R.G., Ray, P.N., Davis, H.L. Hum. Mol. Genet. (1996) [Pubmed]
  26. Expression of the gastrin gene in the normal human colon and colorectal adenocarcinoma. Finley, G.G., Koski, R.A., Melhem, M.F., Pipas, J.M., Meisler, A.I. Cancer Res. (1993) [Pubmed]
  27. Intron-less RNA injected into the nucleus of Xenopus oocytes accesses a regulated translation control pathway. Braddock, M., Muckenthaler, M., White, M.R., Thorburn, A.M., Sommerville, J., Kingsman, A.J., Kingsman, S.M. Nucleic Acids Res. (1994) [Pubmed]
  28. Structural aspects of the human C5 gene. Intron/exon organization, 5'-flanking region features, and characterization of two truncated cDNA clones. Carney, D.F., Haviland, D.L., Noack, D., Wetsel, R.A., Vik, D.P., Tack, B.F. J. Biol. Chem. (1991) [Pubmed]
  29. The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Padalko, E., Nuyens, D., De Palma, A., Verbeken, E., Aerts, J.L., De Clercq, E., Carmeliet, P., Neyts, J. Antimicrob. Agents Chemother. (2004) [Pubmed]
  30. Recombinant human interferon alpha enhancement of retinoic-acid-induced differentiation of HL-60 cells. Kohlhepp, E.A., Condon, M.E., Hamburger, A.W. Exp. Hematol. (1987) [Pubmed]
  31. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study. Elias, L., Blumenstein, B.A., Kish, J., Flanigan, R.C., Wade, J.L., Lowe, B.A., Goodwin, J.W., Crawford, E.D. Cancer (1996) [Pubmed]
  32. Effect of induction therapy on Hepatitis C. Akbar, H.O. Saudi medical journal. (2002) [Pubmed]
  33. A knotted1-like homeobox gene in Arabidopsis is expressed in the vegetative meristem and dramatically alters leaf morphology when overexpressed in transgenic plants. Lincoln, C., Long, J., Yamaguchi, J., Serikawa, K., Hake, S. Plant Cell (1994) [Pubmed]
  34. Intron mutations affect splicing of Saccharomyces cerevisiae SUP53 precursor tRNA. Strobel, M.C., Abelson, J. Mol. Cell. Biol. (1986) [Pubmed]
  35. Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity. Ducrest, A.L., Amacker, M., Mathieu, Y.D., Cuthbert, A.P., Trott, D.A., Newbold, R.F., Nabholz, M., Lingner, J. Cancer Res. (2001) [Pubmed]
  36. Mutation detection in the med and medJ alleles of the sodium channel Scn8a. Unusual splicing due to a minor class AT-AC intron. Kohrman, D.C., Harris, J.B., Meisler, M.H. J. Biol. Chem. (1996) [Pubmed]
  37. Genes encoding isoforms of transcription elongation factor TFIIS in Xenopus and the use of multiple unusual RNA processing signals. Plant, K.E., Hair, A., Morgan, G.T. Nucleic Acids Res. (1996) [Pubmed]
  38. Group II intron splicing in chloroplasts: identificationof mutations determining intron stability and fate of exon RNA. Holländer, V., Kück, U. Nucleic Acids Res. (1999) [Pubmed]
  39. Sentinel lymph node biopsy and melanoma biology. Essner, R. Clin. Cancer Res. (2006) [Pubmed]
  40. Interferon alfa-2b-cyclophosphamide combination studies: in vitro and phase I-II clinical results. Durie, B.G., Clouse, L., Braich, T., Grimm, M., Robertone, A.B. Semin. Oncol. (1986) [Pubmed]
  41. Structure and expression of the murine calcyon gene. Dai, R., Bergson, C. Gene (2003) [Pubmed]
  42. Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia. Golomb, H.M., Fefer, A., Golde, D.W., Ozer, H., Portlock, C., Silber, R., Rappeport, J., Ratain, M.J., Thompson, J., Bonnem, E.M. Semin. Oncol. (1987) [Pubmed]
WikiGenes - Universities